Analysis for ISRG

📈 Growth & Financial Trajectory

Over 8 quarters (2024 Q2 to 2026 Q1), Revenues rose from about $2.01B to $2.77B, a ~38% increase. Net Income grew from ~z$531.5M to ~$821.5M, signaling improving profitability with some quarterly variability. The trend is steady expansion in top-line and bottom-line, supported by ongoing operating execution.

💰 Margins & Cash Flow

• Gross Margin remained robust (roughly mid-60s to low-70s%), underpinning solid operating leverage.
• Operating Margin improved over time, aided by stable SG&A and R&D pacing.
• Cash Flow: Operating cash flow was consistently positive (e.g., 2026 Q1: $911.9M), with investing cash flow largely negative due to capex and financing activity fluctuating.

🛡️ Balance Sheet & Liquidity

Total assets near $20.1B with Equity around $17.7–$17.9B. Current assets about $8.8B vs current liabilities around $1.9B yields a strong liquidity cushion and conservative leverage across the period.

⚠️ Key Drivers & Risks

• Drivers: Growing adoption of robotic surgery and favorable reimbursement dynamics; efficiency gains in the operating model.
• Risks: Cyclicality in medical-device demand and competitive/regulatory pressures; valuation sensitivity to adoption speed.